Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

被引：0

作者：

Shibuki, Taro ^{[1
,2
]}

Otsuka, Taiga ^{[3
,4
]}

Shimokawa, Mototsugu ^{[5
,6
]}

Nakazawa, Junichi ^{[7
]}

Arima, Shiho ^{[8
]}

Fukahori, Masaru ^{[9
,10
]}

Miwa, Keisuke ^{[11
]}

Okabe, Yoshinobu ^{[9
]}

Koga, Futa ^{[12
]}

Ueda, Yujiro ^{[13
]}

Kubotsu, Yoshihito ^{[14
]}

Makiyama, Akitaka ^{[15
,16
]}

Shimokawa, Hozumi ^{[15
]}

Takeshita, Shigeyuki ^{[17
]}

Nishikawa, Kazuo ^{[18
]}

Komori, Azusa ^{[18
,19
]}

Otsu, Satoshi ^{[18
]}

Hosokawa, Ayumu ^{[20
]}

Sakai, Tatsunori ^{[21
]}

Oda, Hisanobu ^{[22
]}

Kawahira, Machiko ^{[23
]}

Arita, Shuji ^{[24
]}

Honda, Takuya ^{[25
]}

Taguchi, Hiroki ^{[7
,26
]}

Tsuneyoshi, Kengo ^{[27
]}

Kawaguchi, Yasunori ^{[28
]}

Fujita, Toshihiro ^{[26
]}

Sakae, Takahiro ^{[26
]}

Nio, Kenta ^{[29
,30
]}

Ide, Yasushi ^{[14
,31
]}

Ureshino, Norio ^{[3
,32
]}

Shirakawa, Tsuyoshi ^{[33
,34
]}

Mizuta, Toshihiko ^{[35
]}

Mitsugi, Kenji ^{[29
,30
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Promot Drug & Diagnost Dev, Div Drug & Diagnost Dev Promot, Translat Res Support Off, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[2] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[3] Saga Ken Med Ctr Koseikan, Dept Med Oncol, 400 Kase Machi, Saga, Saga 8408571, Japan

[4] Minato Med Clin, Dept Internal Med, 3-11-3 Nagahama,Chuo Ku, Fukuoka, Fukuoka 8100072, Japan

[5] Natl Kyushu Canc Ctr, Clin Res Inst, 3-1-1 Notame,Minami Ku, Fukuoka, Fukuoka 8111395, Japan

[6] Yamaguchi Univ, Grad Sch Med, Dept Biostat, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan

[7] Kagoshima City Hosp, Dept Gastroenterol, 37-1 Uearata Cho, Kagoshima, Kagoshima 8908760, Japan

[8] Kagoshima Univ, Grad Sch Med & Dent Sci, Digest & Lifestyle Dis, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908520, Japan

[9] Kurume Univ, Dept Med, Div Gastroenterol, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[10] Kyoto Univ Hosp, Kyoto Innovat Ctr Next Generat Clin Trials & iPS C, 54 Kawaharacho,Shogoin,Sakyo Ku, Kyoto 6068507, Japan

[11] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[12] Saga Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, 400 Kase Machi, Saga, Saga 8408571, Japan

[13] Japanese Red Cross Kumamoto Hosp, Dept Hematol & Oncol, 2-1-1 Nagamine-Minami,Higashi Ku, Kumamoto, Kumamoto 8618520, Japan

[14] Karatsu Red Cross Hosp, Dept Internal Med, 2430 Watada, Karatsu, Saga 8478588, Japan

[15] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, 1-8-1 Kishinoura,Yahatanishi Ku, Kitakyushu, Fukuoka 8068501, Japan

[16] Gifu Univ Hosp, Canc Ctr, 1-1 Yanagido, Gifu 5011194, Japan

[17] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Gastroenterol, 3-15 Morimachi, Nagasaki, Nagasaki 8528511, Japan

[18] Oita Univ, Fac Med, Dept Med Oncol & Hematol, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan

[19] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, 160 Minamiumemoto Cho, Matsuyama, Ehime 7910280, Japan

[20] Univ Miyazaki Hosp, Dept Clin Oncol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan

[21] Natl Hosp Org Kumamoto Med Ctr, Dept Med Oncol, 1-5 Ninomaru,Chuo Ku, Kumamoto, Kumamoto 8600008, Japan

[22] Saiseikai Kumamoto Hosp, Div Integrat Med Oncol, 5-3-1 Oumi,Minami Ku, Kmamoto, Kumamoto 8614193, Japan

[23] Kagoshima Kouseiren Hosp, Dept Gastroenterol, 1-13-1 Yojirou, Kagoshima, Kagoshima 8900062, Japan

[24] Miyazaki Prefectural Miyazaki Hosp, Dept Chemotherapy, Miyazaki, Japan

[25] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki, Nagasaki 8528501, Japan

[26] Saiseikai Sendai Hosp, Dept Gastroenterol, 2-46 Harada Cho, Satsumasendai, Kagoshima 8950074, Japan

[27] Izumi Gen Med Ctr, Dept Gastroenterol, 520 Myoujin Cho, Izumi, Kagoshima 8990131, Japan

[28] Asakura Med Assoc Hosp, Dept Gastroenterol, 422-1 Raiha, Asakura, Fukuoka 8380069, Japan

[29] Sasebo Kyosai Hosp, Dept Med Oncol, 10-17 Shimanji Cho, Sasebo, Nagasaki 8578575, Japan

[30] Hamanomachi Hosp, Dept Med Oncol, 3-3-1 Nagahama,Chuo Ku, Fukuoka, Fukuoka 8108539, Japan

[31] Natl Hosp Org Saga Hosp, Dept Internal Med, 1-20-1 Hinode, Saga, Saga 8498577, Japan

[32] Kimitsu Chuo Hosp, Dept Med Oncol, 1010 Sakurai, Kisarazu, Chiba 2928535, Japan

[33] Eikoh Hosp, 3-8-15 Befu Nishi,Shime Machi, Fukuoka 8112232, Japan

[34] Clin Hematol Oncol Treatment Study Grp, 1-14-6 Muromi Gaoka,Nishi Ku, Fukuoka, Fukuoka 8190030, Japan

[35] Fujikawa Hosp, Dept Internal Med, 1-2-6 Matsubara, Saga, Saga 8400831, Japan

来源：

SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期

关键词：

Pancreatic cancer; Second line; Nanoliposomal irinotecan; S-1; FOLFIRINOX; RANDOMIZED PHASE-II; C-REACTIVE PROTEIN; NAB-PACLITAXEL; 1ST-LINE CHEMOTHERAPY; PLUS GEMCITABINE; SURVIVAL; PROGNOSIS; TRIAL;

D O I：

10.1038/s41598-024-65689-8

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab-paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective studies included 318 patients receiving nanoliposomal irinotecan + 5-fluorouracil/folinic acid (NFF) (n = 102), S-1 (n = 57), or FOLFIRINOX (n = 14) as second-line treatment. Median overall survival (OS) in the NFF group was 9.08 months, significantly better than S-1 (4.90 months, P = 0.002). FOLFIRINOX had a median OS of 4.77 months, not statistically different from NFF. Subgroup analyses of OS indicated NFF was generally superior, however, a statistical interaction was observed between the treatment regimen in serum Alb < 3.5 g/dL (P = 0.042) and serum CRP >= 0.3 mg/dL (P = 0.006). Median progression-free survival (PFS) was 2.93 months for NFF, significantly better than S-1 (2.53 months, P = 0.024), while FOLFIRINOX had a comparable PFS (3.04 months, P = 0.948). Multivariate analysis identified the serum CRP, serum CA19-9, duration of first-line GnP therapy, and use (yes/no) of S-1 for second-line treatment as independent predictors for OS. This study concludes that second-line NFF therapy demonstrated a more favorable OS compared to S-1 therapy, however, it is still important to consider the patient background characteristics while selecting the most appropriate treatment.

引用

页数：10

共 50 条

[31] Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.
Dean, Andrew Peter
Das, Adarsh
McNulty, Meabh
Higgs, Domenic
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[32] FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
Matsumoto, Toshihiko
Kurioka, Yusuke
Okazaki, Ukyo
Matsuo, Yu
Kimura, Shogo
Miura, Kou
Tsuduki, Takao
Takagi, Shinjiro
Takatani, Masahiro
Morishita, Hirofumi
PANCREAS, 2020, 49 (04) : 574 - 578
[33] Clinical outcome of initially unresectable pancreatic cancer patients: Conversion surgery after modified FOLFIRINOX or gemcitabine nab-paclitaxel
Ushida, Yuta
Inoue, Yosuke
Ito, Hiromichi
Ono, Yoshihiro
Sato, Takafumi
Takahashi, Yu
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[34] Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
Fukuchi, Minoru
Mochiki, Erito
Ishiguro, Toru
Ogura, Toshiro
Sobajima, Jun
Kumagai, Youichi
Ishibashi, Keiichiro
Ishida, Hideyuki
ANTICANCER RESEARCH, 2016, 36 (12) : 6699 - 6703
[35] Nab-paclitaxel as second-line treatment in advanced biliary cancer
Unseld, M.
Kornek, G.
Werner, S.
Guenther, S.
Christoph, Z.
Gerald, P.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S431 - S432
[36] CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer
Sam Z. Thalji
Mandana Kamgar
Ben George
Mohammed Aldakkak
Kathleen K. Christians
Callisia N. Clarke
Beth A. Erickson
William A. Hall
Parag P. Tolat
Zachary L. Smith
Douglas B. Evans
Susan Tsai
Annals of Surgical Oncology, 2023, 30 : 3013 - 3021
[37] Feasibility and anti-tumor effect of Gemcitabine plus Nab-Paclitaxel for unresectable pancreatic adenocarcinoma as second-line chemotherapy
Terashima, Takeshi
Yamashita, Tatsuya
Yano, Masaaki
Ooishi, Naoki
Omura, Hitoshi
Mizuno, Hideki
Nomura, Yoshimoto
Takatori, Hajime
Takabatake, Hisashi
Kaneko, Shuichi
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 258 - 258
[38] CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer
Thalji, Sam Z.
Kamgar, Mandana
George, Ben
Aldakkak, Mohammed
Christians, Kathleen K.
Clarke, Callisia N.
Erickson, Beth A.
Hall, William A.
Tolat, Parag P.
Smith, Zachary L.
Evans, Douglas B.
Tsai, Susan
ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (05) : 3013 - 3021
[39] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
Guo Xi
Xu Yaolin
Ji Yuan
Fan Yue
Wang Dansong
Jin Dayong
Zhuang Rongyuan
Wu Lili
Lou Wenhui
Zhou Yuhong
Department of Medical Oncology
Department of General Surgery
Department of Pathology
Department of Traditional Chinese Medicine
Department of Radiotherapy
胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
[40] Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
Merz, Valeria
Cavaliere, Alessandro
Messina, Carlo
Salati, Massimiliano
Zecchetto, Camilla
Casalino, Simona
Milella, Michele
Caffo, Orazio
Melisi, Davide
CANCERS, 2020, 12 (05)

← 1 2 3 4 5 →